Literature DB >> 9759838

Identification of a cytoplasmic region of CD20 required for its redistribution to a detergent-insoluble membrane compartment.

M J Polyak1, S H Tailor, J P Deans.   

Abstract

CD20 is a B lymphocyte integral membrane protein with signal-transducing properties. Abs directed toward extracellular CD20 epitopes activate nonreceptor tyrosine kinases and modulate cell cycle progression of B lymphocytes. Recently, we demonstrated that binding of CD20 Abs to B cells induces the rapid redistribution of up to 95% of CD20 molecules to low density, detergent-insoluble membrane microdomains and induces the appearance of an approximately 50-kDa tyrosine-phosphorylated protein in the same compartment. Active relocalization of CD20 may thus be critical to the initiation of signaling events by CD20. The CD20 cDNA sequence predicts a nonglycosylated protein with four transmembrane-spanning regions and intracellular amino and carboxyl termini. Here we provide verification of the location of both the intracellular and extracellular regions of the CD20 molecule and identify a membrane-proximal sequence in the cytoplasmic carboxyl tail that is required for CD20 to redistribute to detergent-insoluble membrane microdomains.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9759838

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  25 in total

Review 1.  CD20-mediated apoptosis: signalling through lipid rafts.

Authors:  Julie P Deans; Haidong Li; Maria J Polyak
Journal:  Immunology       Date:  2002-10       Impact factor: 7.397

Review 2.  The MS4A family: counting past 1, 2 and 3.

Authors:  Li Eon Kuek; Melanie Leffler; Graham A Mackay; Mark D Hulett
Journal:  Immunol Cell Biol       Date:  2015-04-03       Impact factor: 5.126

3.  Cholesterol depletion inhibits src family kinase-dependent calcium mobilization and apoptosis induced by rituximab crosslinking.

Authors:  Tammy L Unruh; Haidong Li; Cathlin M Mutch; Neda Shariat; Lana Grigoriou; Ratna Sanyal; Christopher B Brown; Julie P Deans
Journal:  Immunology       Date:  2005-10       Impact factor: 7.397

Review 4.  Mechanisms of Resistance to Monoclonal Antibodies (mAbs) in Lymphoid Malignancies.

Authors:  Pallawi Torka; Mathew Barth; Robert Ferdman; Francisco J Hernandez-Ilizaliturri
Journal:  Curr Hematol Malig Rep       Date:  2019-10       Impact factor: 3.952

5.  Antigen sensitivity of CD22-specific chimeric TCR is modulated by target epitope distance from the cell membrane.

Authors:  Scott E James; Philip D Greenberg; Michael C Jensen; Yukang Lin; Jinjuan Wang; Brian G Till; Andrew A Raubitschek; Stephen J Forman; Oliver W Press
Journal:  J Immunol       Date:  2008-05-15       Impact factor: 5.422

6.  Patterns of expression, membrane localization, and effects of ectopic expression suggest a function for MS4a4B, a CD20 homolog in Th1 T cells.

Authors:  Hui Xu; Mark S Williams; Lisa M Spain
Journal:  Blood       Date:  2005-11-17       Impact factor: 22.113

7.  Activatory and inhibitory Fcγ receptors augment rituximab-mediated internalization of CD20 independent of signaling via the cytoplasmic domain.

Authors:  Andrew T Vaughan; Claude H T Chan; Christian Klein; Martin J Glennie; Stephen A Beers; Mark S Cragg
Journal:  J Biol Chem       Date:  2015-01-07       Impact factor: 5.157

8.  Sorting of carboxypeptidase E to the regulated secretory pathway requires interaction of its transmembrane domain with lipid rafts.

Authors:  Chun-Fa Zhang; Savita Dhanvantari; Hong Lou; Y Peng Loh
Journal:  Biochem J       Date:  2003-02-01       Impact factor: 3.857

9.  CD20 mutations involving the rituximab epitope are rare in diffuse large B-cell lymphomas and are not a significant cause of R-CHOP failure.

Authors:  Nathalie A Johnson; Stephen Leach; Bruce Woolcock; Ronald J deLeeuw; Ali Bashashati; Laurie H Sehn; Joseph M Connors; Mukesh Chhanabhai; Angela Brooks-Wilson; Randy D Gascoyne
Journal:  Haematologica       Date:  2009-02-11       Impact factor: 9.941

Review 10.  Cancer therapeutic antibodies come of age: targeting minimal residual disease.

Authors:  Tsipi Ben-Kasus; Bilha Schechter; Michael Sela; Yosef Yarden
Journal:  Mol Oncol       Date:  2007-03-14       Impact factor: 6.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.